Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593997 | 0.92 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12KCNH2SCN5A | |
| SCHEMBL98891 | 0.81 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12KCNH2SCN5A | |
| SCHEMBL18583995 | 0.80 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12KCNH2SCN5A | |
| SCHEMBL19790098 | 0.78 | MKNK2 (0.32) | — | |
| SCHEMBL18593982 | 0.77 | — | — | |
| SCHEMBL10388320 | 0.77 | TSHR (0.40) | FGFR1FGFR4SLC22A12 | |
| SCHEMBL1396237 | 0.76 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12 | |
| SCHEMBL18593999 | 0.74 | HDAC1 (0.36) | — | |
| SCHEMBL31291523 | 0.73 | NOTUM (0.43) | FGFR1FGFR4KCNH2SCN5ASCN9A | |
| SCHEMBL3003619 | 0.73 | NOTUM (0.43) | FGFR1FGFR4KCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308568-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022194782-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-22 | — | — | WO | disclosed |